India's NovaLead Pharma Repurposes Off-the-Shelf Drugs for COVID-19, an Industrial Info Market Brief

---

Indian drug discovery and research company, NovaLead Pharma Private Limited, is set to trial its repurposed COVID-19 drug, which is code-named NLP21. The company claims the drug has shown better efficacy than all the other existing treatments currently being used in the treatment of COVID-19.

The country's top drug regulator, Drug Controller General of India (DCGI), has recently granted approval to NovaLead "in principle" to undertake clinical trials for its repurposed drug.

NovaLead says it has shortlisted 42 available drugs that may have potential to treat COVID-19. Two of these shortlisted drugs were tested by third-party, overseas laboratories. NLP21 is claimed to have the ability to prevent the virus from binding to human cells and thus reducing the viral load and allowing regeneration of healthier cells.

Industrial Info's database covers 31 COVID-19-related Pharmaceutical & Biotech projects worth $309 million India. Click here for a list and see map below.